SIMULTANEOUS PRODUCTION OF TWO CAPSULAR POLYSACCHARIDES BY PNEUMOCOCCUS : I. PROPERTIES OF A PNEUMOCOCCUS MANIFESTING BINARY CAPSULATION by Austrian, Robert & Bernheimer, Harriet P.
SIMULTANEOUS PRODUCTION OF TWO CAPSULAR POLYSAC- 
CHARIDES BY PNEUMOCOCCUS 
I. PROPERTIES OF A PN~DMOCOCCUS ~/~ANI~ESTING  BINARY 
CAPSI)-LATION  * 
Bx ROBERT AUSTRIAN, M.D.,  A~ HARRIET P.  BER-N-HEIMER, PH.D. 
(From the Depart~ment of Medicine, State University of New York College of Medicine 
at New  York  City,  Brooklyn) 
PXAa'ES 32 xO 35 
(Received for publication, June 4,  1959) 
The concept that a pneumococcal cell may produce more than one capsular 
antigen is not new. The possible occurrence of the phenomenon was considered 
as early as  1928 by Griffith  (1),  who described, in his  original  report of the 
transformation reaction, a strain of pneumococcns agglutinated specifically  by 
antisera to two different pneumococcal types. In the same year, the serologic 
cross-reactivity between pneumococcus Type III and a  strain  classified later 
as pneumococcus Type VIII was recognized  (2, 3). It was shown subsequently 
by Goebel (4), however, that the immunologic  relationship between these two 
capsular  types resulted  from  the  presence in their respective capsular poly- 
saccharides of a common chemical  subgroup rather than from the production 
by each type of several discrete capsular antigens, one of which was common 
to both.  Similar  immunologic cross-reactivity has been demonstrated  among 
a number of other pneumococcal types (5), but in no instance has it been shown 
conclusively that an organism of this species produces more than one molecular 
type of capsular polysaccharide. 
In 1953, Leidy, Hahn, and Alexander (6) reported on the production in vitro 
of new types of Hemophilus influenzae obtained by transforming capsulated or 
non-capsulated  organisms  of  this  species  with  deoxyribonucleates  (DNA) 
derived from bacterial cells of heterologons capsular type. Organisms  reacting 
with each of two unitypic anticapsular sera were isolated and,  although defin- 
itive  experiments are  not  described, it  is possible that  these cells were pro- 
ducing  capsular polysaccharides of two molecular species.  Analogous  experi- 
ments performed with pneumococcus have led to the isolation of a variety of 
phenotypes manifesting binary capsulation. In this and in subsequent reports, 
some of their biological,  biochemical,  and genetic properties will be set forth. 
• This investigation  was supported  in part by research  grant  E-1018(C2)  from  the In- 
stitute of Allergy and  Infectious  Diseases, United States  Public Health Service. 
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Materials and Methods 
Nomenclature of Pneumococcal Variants.--In  certain  of the pneumococcal strains  to be 
described, there is lack of complete correspondence between phenotype and  genotype.  For 
this reason, complexities arise in the description of these strains. For the present, only pheno- 
typic designations will be employed and  terms  descriptive of genotype will be introduced 
later. 
Fully capsulated phenotypes are indicated by the letter S followed by a Roman numeral 
designating capsular type; e.g., SIII is a  capsulated strain of pneumococcus Type IlI. Be- 
cause of certain biochemical relationships to be described subsequently and for convenience, 
non-capsulated  variants  and  intermediate  capsular  variants  agghitinable  by  antibody  to 
somatic antigens,  including those described  by Taylor  (7)  under  the term SIII-1, will be 
designated by the expression S-xt, the subscript designating the capsular type from which the 
mutant strain was derived and the strain's designation; e.g., S--III~ is Strain 4 of a non-capsu- 
lated  phenotype  derived  from  pneumococcus  Type  III.  Phentotypes  manifesting  binary 
capsulation will be indicated by the letter S followed by the two Roman numerals descriptive 
of the strain's capsular components separated  by a hyphen; e.g., SI-III is a  pneumococcus 
characterized  by the production  of both  Type  I  and  Type III capsular  polysaecharides. 
Strains of Pneumococcus.--SI phenotypes--SVI, ID, I41S, IP: strains of the SI genotype 
isolated originally from human sources and carried in the laboratory for several years. 
SIII phenotype--IIIA66: a strain of the SIII genotype carried in the laboratory for many 
years. 
S--iil phenotypes-- S-Ill, S-mr:  strains of a  non-capsulated variant of pneumococcus 
Type II (R36A) which carry different mutated Type 1-11 genomes acquired by transformation 
with DNA from variants of Strain IliA55. 
S-I11,: the same  non-capsulated  mutant  of  pneumococcus Type  II  transformed  with 
DNA of a  variant of the Type III Strain SV3.  (The three preceding strains are  Ephrussi- 
Taylor's SIII-I, SIII-Ib, and SIII-Ic (8) and were made available to us by her and  by Dr. 
Arnold Ravin.) 
S--m~: a non-capsulated variant of strain IIIh05. 
Preparation of DNA  (Transforming  Principles)  and  Technique of Transformation Re- 
aa/ons.--The methods used were those described  by MacLeod and  Krauss  (9). 
Preparation of Anticapsular Sera.--Vaecines  of unitypic  pneumococd  and  of pneumo- 
cocci producing two capsular polysaccharides were prepared  from  cultures  grown at 37°C. 
for 12 to 16 hours. After standing for I  hour at room temperature following the addition of 
neutralized formalin to  a  final  concentration  of  1  per  cent,  the  organisms  were collected 
by centrifugation and resuspended in a volume of normal saline solution one-tenth that of the 
original culture. The suspendon was heated at 65°C. for 30 minutes and stored at 4°C. 
Rabbits were immunized by the injection intravenously of 1 co. of vaccine daily for 5 days 
and were bled on the 10th day following each course of vaccine. 
Precipitin Tests.--Precipitin  tests were carried out in small test tubes. 0.2 cc. of each of 
several serial dilutions of antigen was layered over 0.2 ce. of serum. The tubes were incubated 
for 1 hour at 37°C. and the reactions read after the tubes had stood overnight at 4°C. 
Precipitin reactions in agar gels were carried out according to the technique of Ouehterlony 
as modified by Halbert (10). 
Virulence and Protection Tests.--Tests of virulence were performed by the injection intra- 
peritoneally into mice of the CFW strain of 1 ec. of an appropriate dilution of a blood broth 
culture of the strain to be tested which had been incubated for 16 hours. Counts of viable bac- 
terial units were obtained by dilution and  plating.  In protection  tests,  mice were injected 
intraperitoneally with 1 cc.  of the serum to be tested  24 hours before being infected with 
pneumococci as in tests of virulence. Control animals received normal rabbit serum. All tests R. AUSTRIAN AND H. P. BERNHEIMER  573 
were continued for 10 days and results were scored in terms of survival or death. The cause 
of death was determined by culture of the animal's blood at autopsy. In experiments in which 
the enzyme which hydrolyzes specifically Type III capsular polysaccharide  I was employed, 
2 nag. of enzyme were injected intraperitoneaUy. 
Tests of Phagocylosis by Human Polymorphonuclear Leukocytes.--The technique employed 
was one described previously (11). When the enzyme hydrolyzing Type III polysaccharide 
was used, it was present in a final concentration of 2 mg./cc. 
EXPERIMENTAL 
P~notypes Manifesting  Binary  Capsulation.--When  cells  of pneumococcal 
Strain S-m,  are transformed in the presence of DNA from any of the Type 
I  pneumococcal  strains  listed  above,  organisms  of two  different  phenotypes 
can be recovered: cells of the SI phenotype and cells of the SI-III phenotype. 
TABLE  I 
Rdationshlps of Pneumococcal Strains Participating in Transformation Reactions Giving Rise 
to Variants Producing Two Capsular Polysaccharid~ 
Original capsular type of strain 
m aniffoe[lt:mw~mg~  ~r  Sa~i.  if  ioirmPah~inotype  Parent T~e III straln of variant  with S-III genome  Source of SI genome 
SI 
SII 
$III 
SV 
IIIA06 
IIIA66 
IIISV3 
IIIA66 
IIIA66 
SVI 
SVI, ID, I41S, IP 
SVI, ID 
SVI, ID, I41S, IP 
ID 
In  similar fashion,  SI-III strains  may be obtained  by  transforming  cells  of 
lines S--m1, S--m2 and S--mr  From these experiments, it can be seen that 
mutant Type III cells,  the capsular genomes of which were derived originally 
from two different Type III strains,  IIIA56 and IIISV3, can be transformed 
to the SI-III phenotype with DNA from several SI strains. In addition, it is 
evident that non-capsulated cells derived originally from capsulated strains of 
different capsular types, i.e. Type II and Type III, may manifest binary capsu- 
lation when endowed with the proper genetic factors. It has been possible also 
to transform non-capsulated cells derived from Type I and from Type V pneu- 
mococci  to  the  SI-III phenotype.  The  phenomenon  of  binary  capsulation, 
therefore, may be expressed by cells derived from a  variety of capsular types 
when they are endowed with the appropriate genetic factors derived from any 
of several Type I  and mutant Type III strains (Table I). 
1 The enzyme preparation  was made available through the generosity of Dr.  Alan W. 
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SI-III cells were observed first in experiments in which strain  S-HI, had 
been exposed to DNA from a capsulated Type I  strain.  In quellung prepara- 
tions,  ~ it was noted that the transformed cells showed capsular swelling when 
exposed either to Type I  or to Type III antiserum. The size of the refractile 
capsular halo in Type HI antiserum was approximately that seen about cells 
of the normally capsulated Type HI phenotype but the refractile zone about 
cells in Type I  antiserum was distinctly smaller  than  that  about capsulated 
Type I  cells and at times could be seen only with difficulty.  Variation in the 
size of the two capsular components in relation to the phase of bacterial growth 
was not observed. When the cells manifesting b;nary capsulation were exposed 
to a  mixture of Type I  and Type III antisera,  the capsular swelling was not 
recognizably greater than that which followed contact with Type III antiserum 
alone. In smears stained by the Gram technique, such cells showed no consistent 
variation  in  size  or in  shape  which permitted  their  distinction  from singly 
capsulated variants. SI-III cells isolated from the peritoneal cavity of the white 
mouse did show elongated forms often in short chains,  morphologic  charac- 
teristics not manifested by the organism when grown in vitro. 
On  solid  medium,  SI-III  cells  give  rise  to  clones  morphologically  indis- 
tinguishable from those formed by pneumococcus Type III, a  not surprising 
finding  in view of the significant  amount of Type III polysaccharide formed 
by the SLIII cell. 
Evidence Establishing the Existence of the SI-III CelL--The observation that 
more than  90 per cent of cells from clones  of the  SI-III phenotype gave a 
positive quellung  reaction in both Type I  and Type III anticapsular  serum 
provided strong  presumptive evidence for the  existence  of a  cell producing 
two capsular polysaccharides or one so constituted chemically as to possess 
the serologically reactive groups of Type I and of Type III polysaccharide. 
To distinguish between cells manifesting binary capsulation and mixtures of 
SI and SIII cells, several types of experiment were performed. Table II shows 
the results of growing  SI, SIII, mixtures of SI and SIII cells and SI-III cells 
in broth containing either Type I or Type HI anticapsular serum.  Only those 
cells producing simultaneously two capsular polysaccharides are agglutinated 
by both Unitypic antisera and yield cultures with limpid supematant fluids in 
the presence of each antiserum in so called  "thread tests." 
Similar evidence distinguishing  cells with binary capsules from unitypic cells 
has  been obtained from mouse protection  tests.  The  evidence in Table III 
indicates that all animals infected with cells with binary capsules were protected 
by either unitypic capsular antiserum whereas none was protected by either 
2 Capsular typing sera were made available through the courtesy of Dr.  H.  D. Piersma, 
Lederle Laboratories Division, American Cyanamid Company, and Dr. E. F. Roberts, Wyeth 
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antiserum when infection was carried out with mixtures of Type I  and Type 
III cells. 
Evidence for the Production of Two Capsular Polysaccharides by SI-III Cells.-- 
SI-III cells grown by continuous passage in broth containing either Type I or 
Type III anticapsular  serum give rise to mutant cells producing in amounts 
detectable by the quellung reaction only Type III or Type I  capsular poly- 
saccharide.  These mutants  derived from SI-III cells suggest that  separately 
variable factors controlling two capsular components are present in the SI-III 
cell but do not exclude  the possibility that each mutant is associated with a 
qualitative variation in the composition of one of two polysaccharides. 
A second type of evidence is derived from the exposure of SI-III cells to the 
enzyme which hydrolyzes Type III capsular polysaccharide. Mter such treat- 
TABLE  II 
Appearance of Supernatant Fluid of Pneumococcal Cultures Containing Unitypic 
Anlicapsular Serum 
Pneumococcal type or types in culture 
SI 
SIII 
SI  +  SIII 
SI-III 
SI-III  +  SI 
SI-III  +SIII 
Ant/-SI 
L 
T 
T 
L 
L 
T 
Serum 
T 
L 
T 
L 
T 
L 
Medium:  neopeptone  broth  plus  10  per  cent  anticapsular  rabbit  serum;  L  ffi  limpid 
superuatant fluid. T  ffi turbid supernatant fluid. 
ment, SI-III cells are no longer  agglutinable by Type III anticapsular serum 
and they fail to give a quellung reaction with Type III antibody. Their aggluti- 
nability by Type I anticapsular serum remains unimpaired, however, and the 
treated cells give still a  positive quellung reaction with Type I  antibody. It 
has been shown that the action of the enzyme hydrolyzing Type III pneumo- 
coccal polysaccharide is more highly specific than antibody to Type HI poly- 
saccharide.  In  addition,  the  action  of  this  enzyme  has  been  demonstrated 
recently to be that of an endoenzyme rather than that of an exoenzyme attack- 
ing the end-groups of a macromolecule (12). The experiments suggest strongly, 
therefore, that the SI-III cell produces normal Type III polysaccharide or a 
substance resembling it very closely and one that is probably distinct from the 
Type I component of the capsule. 
In precipitin reactions carried out in an agar gel by the modified  technique 
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antibody is allowed to react in the same plate with SI-III cells, SIII cells and 
Type III polysaccharide give rise to a line of continuity (Fig.  1); and, in like 
manner, a line of continuity is produced when the reactants are Type I anti- 
capsular antibody, SI-III cells and Type I polysaccharide (Fig. 2). 
Precipitin  tests  performed  with  partially  purified  polysaccharides  from 
SI-III cells show that  the Type III polysaccharide can be precipitated by 
Type III anticapsular serum without significant  removal of the Type I  corn- 
TABLE  III 
Protevtive E fext of Type I  and Type III Antiserum in Mice Infected with SI-III and with 
Mixtures of SI and SIII Pneumococci 
Strain  Amount of culture injected  Serum injected  D/S* 
SI-III  10-6 
lo-  6 
10-6 
10-6 
lo-  ~ 
10-8 
Anti-SI 
Anti-SIII 
Normal 
None 
None 
None 
0/6 
0/6 
6/0 
6/o 
5/t 
5/1 
Viable units/cc. (undiluted culture) : 4 ×  los 
Strains 
SI  +  SIII 
Amount of culture injected 
lo-  o 
lo-  s 
lo-  6 
10-6 
lo-7 
lo-  s 
Seruminjected 
Anti-SI 
Anti-SIII 
Normal 
None 
None 
None 
D/S* 
6/0 
6/0 
6/0 
6/o 
6/0 
4/2 
Viable uuits/cc,  undiluted culture) : 3 X  l0  s (equal numbers of SI +  SlID 
* D/S =  died/survived. 
ponent of the capsule  and  conversely,  specific precipitation of the Type I 
capsular component is not accompanied by removal of the Type III component 
from solution. 
A 200 cc. culture of SI-III cells was grown overnight after which time glucose was added 
to a  final concentration of 1 per cent. During an additional 6 hours' incubation, the lactic 
acid formed was neutralized by the addition of 3 N NaOH.  The cells were then removed by 
centrifugation and 1 volume of 95 per cent ethyl alcohol was added to the separated super- 
natant fluid.  The suspension was stored overnight at 4°C.  after which time, the precipitate 
formed was collected by centrifugation and dissolved in 10 cc. of normal salt solution. This 
solution served as  the unfractionated capsular  antigen.  Aliquots thereof were allowed to R. AUSTRIAN AND H. P. BERNHEIMER  577 
react  with appropriate  amounts of Type I  or  Type III  anticapsular rabbit  serum or with 
normal rabbit  serum. All volumes were adjusted  to give the same quantity of the original 
antigen in precipifin tests. The results are shown in Table IV. 
On the bases of the independent variability of its capsular components,  of 
the susceptibility of the Type III capsular  component to the enzyme hydro- 
TABLE  IV 
Independent Preclpitability of Each Capsular Component of the SI-II1 Phenotype by Unityplc 
Capsular Antiserum 
Serum 
Anti-SI 
Anti-SIII 
Normal 
Serum 
Anti-SI 
Anti-SIII 
Normal 
Polysaccharide precipitated after treatment with normal rabbit serum 
Dilution of antigen 
1:32 
+++ 
b+++ 
o 
1:64  1:128  1:256 
++  ++  + 
+++  ++  ++ 
o  o  o 
I 
1:512 1:1024 1:2048,1:4096 1:81921  C 
±  o  o  o  o  o 
+  +  +  ±  o  io 
Polysaccharide  precipitated after treatment with type I anticapsular rabbit serum 
Dilution of antigen 
i 
±  I  o  Io  Io  Io  Io  o  o  o  io 
++o+++o+++++++1+  +  o  o[o 
Polysaccharide  precipitated after treatment with type III anticapsular rabbit serum 
Dilution of antigen 
Serum  .........  1:32  1:64  1:128  1:256  1:5121:10241:20481:40961:8192  C 
Anfi-SI  ++  +  +  -4-  0  0  0  0  0  0 
Anti-SIII  ,  0  0  0  0  0  0  0  0  0  0  io  Normal 
lyzing Type III pneumococcal polysaccharide,  of the serologic cross-reactivity 
of its cells with Type I and Type III polysaccharides in precipitin tests in agar 
gels, and of the independent precipitability of its two capsular  components, 
SI-III cells may be considered to produce two capsular polysaccharides. 
Phagocytosis of Sl-lll Cells by Human  Polymorphonudear Leukocytes.--In 
Table V are shown the results  of exposing SI-III cells to human polymorpho- 578  PRODUCTION OF CAPSULAR POLYSACCIIARIDES. I 
nuclear leukocytes in a  smooth-walled  system. Several  facts of interest are 
demonstrable in these experiments. First, the persistence of the antiphagocytic 
effect of the Type III capsular component is demonstrable even in the presence 
of Type I  anticapsular serum. That the Type I  antiserum is fully effective is 
shown in the last line of the table.  Second, the relatively small antiphagocytic 
effect of the Type I  capsular  component becomes apparent when the SI-III 
cells are  exposed to the enzyme depolymerizing Type III polysaccharide  to- 
gether with normal rabbit serum. The efficacy of Type I antibody is definitely 
demonstrable  in the presence of the same enzyme, however, by a further in- 
crease in phagocytosis. 
The Relative  Importance of the Two Capsular Components to the  Virulence of 
SI-III Pneumococci.--Table VI shows the effect of several reagents upon the 
TABLE V 
Pkagocytosis of SI-III Pneumococd by Human Polymorphonuclear Leukocytes  in the Presence 
of Various Sera and of the Enzyme Hydrolyzln~ Type III Polysaccharide 
Per cent PMN con-  Average No. of pneu- 
Strain  Serum  Enzyme  mining pneumococci  mococci per PMN 
SI-III 
SI 
Anti-SI 
Anti-SIII 
Normal 
Anti-SI 
Anti-SIII 
Normal 
Anti-SI 
Absent 
¢¢ 
¢4 
Present 
ac 
cc 
Absent 
8 
100 
4 
96 
96 
32 
88 
0.36 
10.0 
0.08 
8.2 
8.0 
0.92 
8.0 
outcome of infection with SI-III cells in mice. It may be seen that each capsular 
polysaccharide  contributes  to  the  virulence  of  the  infecting organism.  Of 
interest is the role played by the Type I  capsular  component.  Although the 
number of animals  infected is small,  it may be noted that the only animal 
infected with pneumococci manifesting binary capsulation and not receiving 
antiserum to survive was one treated with the enzyme depolymerizing Type 
III polysaccharide.  Not shown in the table but noteworthy also is the fact 
that animals treated with a single injection of enzyme at the time of infection 
survived twice  as  long after inoculation as  did untreated controls.  Similar 
results have been observed  in analogous  experiments  performed with cells of 
the binary capsular  SlII-V phenotype. These observations  are in accord with 
those derived  from the study of phagocytosis  of these strains. They suggest 
that the smaller Type I capsular component is able to protect the population 
of SI-III cens from complete elimination during the period that the enzyme is 
still hydrolyzing effectively the Type III capsular component but is unable by R. AUSTRIAN AND  H. P. BERNHEIMER  579 
itself to shift the balance of infection decisively in favor of the pneumococcus. 
Later,  when the enzyme is no longer effective,  regeneration of the Type III 
capsular  component provides more effective protection against  phagocytosis 
and permits rapid progression  of the infection to a fatal outcome. 
Properties  of Antiserum  Prepared with  Vaccines of SI-III  Pneumococci.-- 
Rabbits immunized with vaccines of pneumococci manifesting  binary capsu- 
lation form antibodies to each of the capsular components of such cells. The 
relative amount of antibody to each of the capsular antigens may vary during 
the course of immunization.  Antisera to SI-III cells cause capsular swelling of 
SI, SIII, SI-III, and SIII-V cells. Shown in Table VII is the protective effect 
TABLE  VI 
Effect of the Ensyme Hydrolyzing  Type IIl Polysacckaride and of Unitypic  Antisera on tke 
V#ulence of SI-III Pneumococci 
Strain 
SI-III 
SI 
sIII 
Amount of culture 
injected 
C~. 
lO-~ 
lO-e 
lO-e 
lO-S 
lO-6 
10-z 
lO-e 
10-6 
10-6 
Serum injected 
None 
Anti-SIII 
Anti-SIII 
Anti-SI 
None 
c~ 
cl 
Anti-SIII 
Enzyme injected 
mg. 
2 
2 
None 
Ic 
c# 
2 
2 
None 
DIS 
3/1 
o14 
o14 
o/4 
31o 
2/o 
4/0 
0/4 
o/4 
Viable units/cc. (undiluted culture): SI-III  =  2  X  108; SI --- 2  X  108; SIII=  3  X  108. 
of such antiserum  in mice infected with cells of each of the aforementioned 
phenotypes and with mixtures of SI and SIII ceils. Recorded also in the table is 
the absence of protection against infection with pneumococcus Type V. Ana- 
logous results are observed in experiments concerned with the phagocytosis of 
pneumococci of several capsular types in the presence of Type I-III antiserum 
(Table VIII). 
Precipitin tests in an agar gel (Fig. 3) disclose several facts. First, with Type 
I  cells  and  Type I  capsular  polysaccharide,  the  anti-SI-III  serum forms  a 
continuous band of precipitate, and with Type III cells and Type III capsular 
polysaccharide a  second and  distinct  band is formed.  Second,  these lines  of 
precipitate are continuous with those formed by the antibody reacting with 
each of the capsular components of the SI-III cell. Third,  there is no band of 
precipitate  formed  to  indicate  the  presence  of  a  single  species  of  antibody TABLE VII 
Protective Effecl of Type 1-III  Antiserum  in Mice Infected with Pneumococci of a  Variety 
of Capsular Types 
Strain or strains  Amount of culture  injected  Serum injected  D/S 
SI-III 
SI 
SIII 
SI  +  SIII 
SIII-V 
SV 
SIII  +  SV 
SI-III 
SI 
SIII 
SI  +  SIII 
SIII-V 
SV 
SIII  +  SV 
SI-III 
SI 
SIII 
SI  +  SIII 
SIII-V 
SV 
SIII +  SV 
10-  6 
10-  6 
10-  6 
10-  6 
10-6 
10-  6 
10-6 
10-6 
10-  e 
10-6 
10-6 
10-  6 
10-  6 
lO-7 
10-  7 
10-  7 
10-7 
10-  7 
10-  7 
lo--  7 
Anti-SI-III 
tL 
ct 
Normal 
tc 
~c 
None 
o/5 
0/5 
0/5 
0/5 
0/5 
s/o 
5/0 
5/o 
s/o 
5/0 
5/o 
5/0 
5/0 
s/o 
2/0 
2/0 
2/0 
2/0 
3/0 
2/0 
2/0 
Viable units/cc. (undiluted culture): SI-III =  5 X  108; SI =  3 X  108; SIII -- 2 X  10s; 
SI+SIII--2X108;SIII-V=2X108;SV--2X10s;SIII+SV=  2X  108. 
TABLE  VIII 
Phagoeyiosis of Pneumococci of Several Types by Human Polymorphonuclear  I_~'ukocytes in the 
Presence of Type I-III Araica Osular Rabbit Serum 
Strain 
SI-III 
SI 
SIII 
SIII-V 
SV 
SI-III 
SI 
SIII 
SIII-V 
SV 
Serum 
Anti-SI-III 
*c 
Normal 
c~ 
PMN conts~,  g 
pnenxno¢occl 
per cent 
84 
6O 
92 
72 
0 
Average.No. of 
pneumococct per  PMN 
8.6 
9.4 
8.1 
7.4 
0 
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reacting  with both capsular components or the presence of a  capsular com- 
ponent  reacting  with  antibody in  a  fashion  different from that  of unitypic 
cells.  The  results  are consistent with  those presented  earlier which indicate 
that  cells  manifesting  binary  capsulation  produce  two  species  of  capsular 
polysaccharide each of which is closely similar  if not identical with that of the 
corresponding  unitypic pneumococcus. 
In precipitin tests performed in tubes, Type I polysaccharide and Type III 
polysaccharide are each precipitated by antiserum prepared with a vaccine of 
TABLE IX 
Independen~ Precipitability of Capsular Antibodies from an Antiserum Prepared with a 
Vaccine of SI-III Pneumococci 
Antigen 
Polysaccharide  precipitated  by anti SI III serum before  absorption 
Dilution of antigen 
Antigen*  1:8  1:16  1:32  1:64  1:128  1:256 1:512 1:1024  1:2048 1:4096 1:8192  C 
s~  ++J++++l++++l++++J  +++1  ++1  +1  +1  *1  41  o I  o 
÷4÷41+4441÷÷÷÷144441  ++41  ÷41  +÷1  41  *[  °1  °1° 
Polysaccharide  precipitated  by antl SI III serum after absorption with SI cells 
Dilution of antigen 
1'8.0  . 0.~0  . 0___~0  .  0__~_[.__~ -  .1'16  1.321  1"64  1"128  1"256 1"512 1"1024 1"20480 1:t0% ____1:8192  C 
+4++ +4+4+444  44÷4 +++4  44+  44  44  +  o  °  o  ° 
Polysaccharlde  precipitated  by antl SI III serum after absorption with SIII cells 
Dilution of antigen 
I  1 16  [  1 321I  1 64t__1.1281  __1:256  __1:$12  __1:1024  i  1:4096 ----1:8192  C  Antigen  18  i  --120 
SIII  +4+  +4q-+  ÷4++1+4++  +÷÷+  01  01  0  I  0 ]  0  I  0  SI  ~  0  0  0  0 ++++1+++]  +  ]  0 J  0 } 0 
* Saline solution of purified Type I or Type III capsular polysaccharlde  in a concentration of I mg./cc, diluted 
as indicated. 
SI-III cells. That two distinct anticapsular antibodies are present in such an 
antiserum  can be demonstrated  by the independent  precipitability of  each. 
When an antiserum prepared with a vaccine of SI-III cells is absorbed with 
either  capsulated  Type I  or Type III  cells,  the  corresponding  anticapsular 
antibody is  removed without  significant  alteration  of  the  titer  of antibody 
precipitating the other capsular component (Table IX). Analogous experiments 
in which precipitin reactions were carried out in an agar gel demonstrate the 
independent removal of one capsular antibody without alteration in the reaction 
of the other with appropriate antigens (Figs. 4 to 6). 582  PRODUCTION  OF CAPSULAR POLYSACCHARIDES. I 
Properties of Deoxyribonucleates of Pneumococci of the SI-III Phenotype.--To 
determine the nature of the genetic determinants of the capsular components 
of the SI-III cell, DNA was prepared from cultures of such ceils in the usual 
manner.  When  ceils  of  a  non-capsulated  pneumococcns  (R36NC)  derived 
originally  from a strain of capsular Type II were exposed in the transforming 
system to DNA from SI-III cells, organisms  of three different phenotypes were 
recovered:  S--H~,  SI and  SI-III.  No  SIII  cells  were observed. The  results 
indicate that there has been no major alteration in either of the genetic units 
concerned with the formation of the two capsular components of the cell mani- 
festing binary capsulation during their residence within that cell and that each 
is able to engender expression  of that  character  controlled by it  when  it  is 
reintroduced  as  the  sole  genetic  factor  concerned  with  capsular  formation 
into another pneumococcal cell. 
DISCUSSION 
Through the agency of the transformation reaction, it has been possible to 
isolate  pneumococci  manifesting  binary  capsulation  of  several  phenotypes. 
Examination  of cells  of the  SI-III  phenotype in  a  number of experimental 
systems reveals  that  organisms  of  this  type produce  two  distinct  capsular 
polysaccharides which are closely similar  if not identical to those produced by 
cells of the corresponding  unitypic phenotypes. The evidence available suggests 
that the two types of polysaccharide are intermingled in the capsule in a random 
fashion. Study of cells of the SIII-V phenotype yields results of a similar nature. 
Binary  capsulation  in  pneumococcus  provides  a  new  basis  for  serologic 
cross-reactivity in this species. Cells manifesting binary capsulation react with 
unitypic antiserum  to  each of their  capsular components and  stimulate  the 
formation of antibodies which will react with cells bearing either of the capsular 
antigens produced by cells of the binary capsular phenotype. Whether or not 
pneumococci manifesting  binary capsulation  exist  in  nature  remains  an  un- 
answered question. Examination by genetic and serologic techniques of several 
groups  of pneumococcal strains  the  capsular  antigens  of which show cross- 
reactivity has failed to result in the recognition in any of the strains of separable 
capsular antigens.  It would appear more likely that the serologic interrelation- 
ships of these strains  are based upon the presence  of common chemical  sub- 
groups in their single capsular polysaccharides rather than upon their production 
of multiple types of capsular polysaccharide. For this reason the nomenclature 
of pneumococcal types proposed by Eddy (13) seems preferable to that proposed 
by Kauffmann  and Lund (14). 
These  experiments  with  pneumococcns  show  many  similarities  to  those 
performed with H. influenzae by Leidy, Hahn, and Alexander (6), and it ap- 
pears probable that binary capsulation may be manifested by organisms of the R. AUSTRJAN AND H. P. BERNttF.T~'I~.R  583 
latter species. In each, however, it would appear to represent a product of the 
laboratory. This  fact notwithstanding,  binary  capsulation provides a  useful 
object for the study of a variety of biologic phenomena. 
SI.~r~ARY 
Pneumococci manifesting binary capsulation  have been produced through 
the agency of transformation reactions. Such cells produce two capsular poly- 
saccharides which are closely similar if not identical with those produced by 
corresponding singly capsulated strains. 
Binary  capsulation  in  pneumococcns  provides  a  new  basis  for  serologic 
cross-reactivity in this species. 
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EXPLANATION OF PLATES 
PLATE 32 
FIG. 1. Reaction of Type III anticapsular  antibody (A) with Type III cells (]3), 
Type I-III cells (c), and Type III capsular polysaccharide  (D). 
FIo. 2. Reaction of Type I anticapsular  antibody (A) with Type I cells (B), Type 
I-III cells (c), and Type I capsular polysaccharide  (D). THE  JOURNAL  OF  EXPERI1V[ENTAL MEDICINE  VOL. 110  PLATE  32 
(Austrian and Bernheimer: Production of capsular polysaccharides. I) PLATE 33 
FIG.  3. Reaction of Type I-III anticapsular serum  (A)  with Type I-III cells  (B), 
Type I  cells  (C), Type I  polysaccharide  (D), Type III cells  (E)  and Type III poly- 
saccharide (F). THE  JOURNAL  OF  EXPERLXJiENTAL  MEDICINE  VOL.  110  PLATE  33 
(Austrian and Bernheimer: Production of capsular polysaccharides. I) PLATE 34 
FIG. 4.  Reaction of Type I-III anticapsular  serum absorbed with Type III pneu- 
mococci (A), with Type I-III cells (B), Type I  cells (C), Type I polysaccharide (D), 
Type III cells (E) and Type III polysaccharide (F). THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  110  PLATE  34 
(Austrian and Bernheimer: Production of capsular polysaccharides. I) PLATE 35 
FIG. 5.  Reaction of Type I-Ill anticapsular  serum  absorbed  with  Type I  pneu- 
mococci (A), with Type I-1II cells (B), Type I  cells (C), Type I polysaccharide (D), 
Type lII cells (E), and Type III polysaccharide (F). 
FrG. 6. Reaction of Type I-III cells (A) with Type I-III antiserum  (B), Type I-III 
antiserum  absorbed  with Type I  pneumococci  (C),  Type III antiserum  (D), Type 
l-III serum absorbed  with  Type III pneumococci  (E),  and  Type I  antiserum  (F). 
Reactions between (A) and (F) failed to develop sufficiently  to be visible  in the photo- 
graph. TItE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL. 110  PLATE  35 
(Austrian and Bernheimer: Production of capsular polysaccharides. I) 